What We’re Asking of Congress
- Ensure best use of scarce federal dollars
- Continue aggressive pursuit of promising science
- Improve coordination to support a wide range of priority research areas
ZERO advocates for the National Cancer Institute (NCI) to convene regular, public meetings of a prostate cancer research coordinating committee. The committee should include designees from other U.S. Department of Health and Human Services (HHS) agencies, like the Health Resources and Services Administration (HRSA), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), as well as the Department of Defense (DoD), private research foundations, and advocacy organizations.
The NCI at the National Institutes of Health (NIH) is responsible for the nation’s largest prostate cancer research program. NCI prostate cancer work spans across several different programs, utilizing various mechanisms for proposal competition. Many programs within NCI are complementary to the ongoing work of the Prostate Cancer Research Program (PCRP) at the DoD.
On behalf of the thousands of American men and the families of those who are living with or may be diagnosed with prostate cancer this year, we ask for Congress’ support of the report language in the Labor-HHS-Education FY2017 appropriations bill instructing the NCI to create a prostate cancer research coordinating committee.
(receive alerts on how to help ensure coordination and transparency from our government agencies)
Congress’ Current Recommendations to NCI
“The Committee is aware of NCI’s ongoing investment in prostate cancer research, but is concerned that prostate cancer lacks treatments for men with advancing disease as well as adequate diagnostic and imaging methodologies common in other hormone-driven cancers with similar disease burden. The Committee encourages NCI to coordinate with other Federal agencies, including the Department of Defense, private research foundations, and other stakeholders. Further, the Committee encourages NIH and CDC to consider how to develop a joint public/private partnership aimed at reducing the prevalence of prostate cancer in African American men. The Committee requests NIH and CDC provide a joint response on this type of effort in the fiscal year 2018 budget request.”
“The Committee is aware of NCI’s ongoing investment in prostate cancer research, and encourages further efforts into treatments for men with advanced disease as well as diagnostic and imaging methodologies common in other hormone-driven cancers with similar disease burden. The Committee encourages NCI to coordinate its response to these needs with other Federal agencies, and collaborators as appropriate, including the Department of Defense, as well as private research foundations and advocacy groups.”